# Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

> **NCT00600587** · PHASE2 · COMPLETED · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 24 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** neoadjuvant erlotinib therapy
- **DRUG:** neoadjuvant gemcitabine/carboplatin therapy

## Key facts

- **NCT ID:** NCT00600587
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600587, "Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00600587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*